# Combined top 10 from each PICO category for Θεραπευτικά_Πρωτόκολλα_ΕΟΠΕ-10η_Έκδοση_cleaned.json

## Population

1. (Patients, score 9) 2;11:193, x.
33.Kudo M, Finn RS, Qin S et al; Lenvatinib versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar
34.Bruix J, Qin S, Merle P, Granito A et al ; RESORCE Investigators. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-
blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66. Epub 2016 Dec 6
35.Abou-Alfa GK, Meyer T, Cheng AL et al ; Cabozantinib in patients with advanced and progressing
hepat

2. (Patients, score 9) ORCE Investigators. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-
blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66. Epub 2016 Dec 6
35.Abou-Alfa GK, Meyer T, Cheng AL et al ; Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med. 2018 Jul 5;379(1):54-63
36.Zhu AX, Kang YK, Yen CJ ae al , ; REACH-2 study investigators. Ramucirumab after sorafenib in patients
with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a
rand

3. (Patients, score 9) Jan 7;389(10064):56-66. Epub 2016 Dec 6
35.Abou-Alfa GK, Meyer T, Cheng AL et al ; Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med. 2018 Jul 5;379(1):54-63
36.Zhu AX, Kang YK, Yen CJ ae al , ; REACH-2 study investigators. Ramucirumab after sorafenib in patients
with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282-296.
37.El-Khoueiry AB, Sangro B, Yau T et al; Nivolumab in patients with advanced hepatocellular carcinoma
(C

4. (Patients, score 9) stigators. Ramucirumab after sorafenib in patients
with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282-296.
37.El-Khoueiry AB, Sangro B, Yau T et al; Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet.
2017 Jun 24;389(10088):2492-2502.
38.Zhu AX, Finn RS, Edeline J et al; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced
hepatocellular car

5. (Patients, score 9) th cancer, especially that attributable to cancer
treatment. Health Technol Assess 2007;11:1-202.
5. Ludwig H, Van Belle S, Barrett-Lee, et al The European Cancer Anaemia Survey (ECAS): a large,
multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in
cancer patients. Eur J Cancer 2004;40:2293-2306.
6. Jabbour E, Kantarjian HM, Koller C, Taher A Red blood cell transfusions and iron overload in the
treatment of patients with myelodysplastic syndromes. Cancer 2008;112:1089-1095.
7. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple m

6. (Patients, score 9) Cancer Anaemia Survey (ECAS): a large,
multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in
cancer patients. Eur J Cancer 2004;40:2293-2306.
6. Jabbour E, Kantarjian HM, Koller C, Taher A Red blood cell transfusions and iron overload in the
treatment of patients with myelodysplastic syndromes. Cancer 2008;112:1089-1095.
7. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and
lymphoma: findings of the European Cander Anaemia Survey. Eur J Haematol 2006;77:378-386.
8.  (last accessed 8 May 2009).
9. Harper P, Littlewoo

7. (Patients, score 9) aemia in
cancer patients. Eur J Cancer 2004;40:2293-2306.
6. Jabbour E, Kantarjian HM, Koller C, Taher A Red blood cell transfusions and iron overload in the
treatment of patients with myelodysplastic syndromes. Cancer 2008;112:1089-1095.
7. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and
lymphoma: findings of the European Cander Anaemia Survey. Eur J Haematol 2006;77:378-386.
8.  (last accessed 8 May 2009).
9. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and long-term outcome.
Oncology 2005;69 Suppl 2:2-7.
αρχική εκτίμηση και η περι

8. (Patients, score 9) 10. Nicolatou-Galitis O, Papadopoulou E, Vardas E, et al (2020) Alveolar bone histological necrosis observed
prior to extractions in patients, who receive bone-targeting agents. Oral Dis 26: 955-966.
11. Ristow O, et al (2021a). Wound closure and alveoloplasty after preventive tooth extractions in patients
with antiresorptive intake-A randomized pilot study. Oral Diseases 27:532-546.
12. Ristow O, et al (2021b). Diagnostic accuracy comparing OPG and CBCT in the detection of non-vital bone
changes before tooth extractions in patients with antiresorptive intake. Oral Diseases, 2021:00:1-11, 7
October 2

9. (Patients, score 9) ound closure and alveoloplasty after preventive tooth extractions in patients
with antiresorptive intake-A randomized pilot study. Oral Diseases 27:532-546.
12. Ristow O, et al (2021b). Diagnostic accuracy comparing OPG and CBCT in the detection of non-vital bone
changes before tooth extractions in patients with antiresorptive intake. Oral Diseases, 2021:00:1-11, 7
October 2021.
13. Otto S, Pautke C, Van den Wyngaert T, et al (2018). Medication-related osteonecrosis of the jaw:
Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treatment
Reviews 69:177-187.
14. Fu

10. (Patients, score 9) a H, et al. Docetaxel and cisplatin in first line treatment of patients with
Row 18: nown primary cancer: a multicenter study of the anatolian society of medical oncology. Asian Pac J
Row 19: cer Prev. 2014;15(4):1581–1584.
Row 20: emori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of Row 1: 
Row 2: 42. Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus
Row 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a Row 1: review of 56 cases. Cancer 1987; 59:572.
Row 2: 44. Mukai H,

## Intervention

1. (Treatment, score 8) Arnedos M, Popat S,Platinum-based chemotherapy in triple-negative breast cancer.Ann Oncol.
2008 Nov;19(11):1847-52. Epub 2008 Jun 20
75.Angelo Di Leo, Henry L. Gomez, Zeba Aziz. Phase III, Double-Blind, Randomized Study Comparing
Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast
Cancer J Clin Oncol 26:5544-5552,2008
76.Kimberly L. Blackwell, Harold J. Burstein, Anna Maria Storniolo Randomized Study of Lapatinib Alone or
in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic
Breast Cancer. J Clin Oncol 28:1124-1

2. (Treatment, score 8) , Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma N Engl J Med. 2008 Jul
2. Martin RC, Jarnagin WR. Randomized clinical trials in hepatocellular carcinoma and biliary cancer. Surg
Oncol Clin N Am 2002;11:193, x.
33.Kudo M, Finn RS, Qin S et al; Lenvatinib versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar
34.Bruix J, Qin S, Merle P, Granito A et al ; RESORCE Investigators. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomi

3. (Treatment, score 7) Anna Maria Storniolo Randomized Study of Lapatinib Alone or
in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic
Breast Cancer. J Clin Oncol 28:1124-1130,2010
77.Kaufman B, Mackey JR, Clemens MR Trastuzumab plus anastrozole versus anastrozole alone for the
treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone
receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin
Oncol. 2009 Nov 20;27(33):5529-37. Epub 2009 Sep 28
solid tumours: integrated analysis of three phase 1-2 tr

4. (Treatment, score 7) Pac J
Row 19: cer Prev. 2014;15(4):1581–1584.
Row 20: emori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of Row 1: 
Row 2: 42. Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus
Row 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a Row 1: review of 56 cases. Cancer 1987; 59:572.
Row 2: 44. Mukai H, Katsumata N, Ando M, et al. Safety and efficacy of a combination of docetaxel and cisplatin in
Row 3: patients with unknown primary cancer. Am J Clin Oncol. 2010;33:32–35.
Row 4

5. (Treatment, score 7) ugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM Jr, Camoriano JK,|n JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM Jr, Camoriano JK,
Row 3: Novotny PJ, Christensen BJ. Randomized comparison of megestrol acetate versus dexamethasone versus|
Row 4: fluoxymesterone for the treatment of cancer anorexia/cachexia. J ClinOncol. 1999;17(10):3299.|
Row 5: |
Row 6: 15. Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. .ROMANA 3: a phase 3 safety extension|
Row 7: study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.AnnOncol.|
Row

6. (Treatment, score 7) acute confusional states).JAMA. 1987;258(13):1789.
Row 3: 4. Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. Am J Psychiatry 1983; 140:1048.
Row 4: 5. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and
Row 5: lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153:231.
Row 6: 6. Hui D, Frisbee-Hume S, Wilson A, et al. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on
Row 7: Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical
Row 8:

7. (Drug, score 7) HR 0.70 (95% CI, 0.58–0.83)] , όσο και στον συνολικό πληθυσμό [18.7 (15.6–21.3) vs 11.9 (10.7–13.3); 0.65 95% CI,
Στους HER-2 θετικούς όγκους, που έχουν υποτροπιάσει μετά από θεραπεία 1ης γραμμής στην οποία
συμπεριλαμβανόταν το Trastuzumab, δύναται να λάβουν συνέχιση θεραπείας, με τον ADC (Antibody Drug
Conjugate) παράγοντα Trastuzumab Deruxtecan,το οποίο έλαβε πρόσφατα έγκριση από τον FDA σύμφωνα με την
μελέτη φάσης 2 Destiny PanTumor 02, στην οποία εντάχθηκαν από τους 268 ασθενείς με διάφορους συμπαγείς
όγκους 40 ασθενείς με καρκίνο του ενδομητρίου, με ικανοποιητικά ποσοστά ανταποκρίσεων (ORR: 5

8. (Treatment, score 6) καθώς και ειδικά στους
ογκολογικούς ασθενείς μέσω της πανευρωπαικής μελέτης NACASY [12] και άλλων μελετών [13-14]. Η
σ υνιστώμενη δόση της ναλοξεγκόλης, είναι 25 mg άπαξ ημερησίως [24].
1. ESMO Minimum Clinical Recommendations: Chemotherapy-induced nausea and vomiting.
2. Gralla RJ: New agents, new treatment, and antiemetic therapy. Semin Oncol 2002; 29 (Suppl 4): 119–24.3.
3. Licitra L, Spinazze S, Roila F: Antiemetic therapy. Crit Rev Oncol Hematol 2002; 43: 93–101.
4. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and
vomiting (CINV): a comprehensive

9. (Therapy, score 6) ολογικούς ασθενείς μέσω της πανευρωπαικής μελέτης NACASY [12] και άλλων μελετών [13-14]. Η
σ υνιστώμενη δόση της ναλοξεγκόλης, είναι 25 mg άπαξ ημερησίως [24].
1. ESMO Minimum Clinical Recommendations: Chemotherapy-induced nausea and vomiting.
2. Gralla RJ: New agents, new treatment, and antiemetic therapy. Semin Oncol 2002; 29 (Suppl 4): 119–24.3.
3. Licitra L, Spinazze S, Roila F: Antiemetic therapy. Crit Rev Oncol Hematol 2002; 43: 93–101.
4. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and
vomiting (CINV): a comprehensive review. Ann Oncol. 2015

10. (Therapy, score 6) τώμενη δόση της ναλοξεγκόλης, είναι 25 mg άπαξ ημερησίως [24].
1. ESMO Minimum Clinical Recommendations: Chemotherapy-induced nausea and vomiting.
2. Gralla RJ: New agents, new treatment, and antiemetic therapy. Semin Oncol 2002; 29 (Suppl 4): 119–24.3.
3. Licitra L, Spinazze S, Roila F: Antiemetic therapy. Crit Rev Oncol Hematol 2002; 43: 93–101.
4. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and
vomiting (CINV): a comprehensive review. Ann Oncol. 2015 Jun;26(6):1081-90.
5. Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D. Aprepitant an

## Comparator

1. (Placebo, score 4) Cancer-related fatigue: prevalence of proposed
diagnostic criteria in a United States sample of cancer survivors.J Clin Oncol. 2001;19(14):3385.
3. Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T, Palmer JL . Patient-controlled methylphenidate for
cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2006;24(13):2073.
4. Spathis A, Dhillan R, Booden D, Forbes K, Vrotsou K, Fife K. Modafinil for the treatment of fatigue in lung
cancer: a pilot study. Palliat Med. 2009;23(4):325.
5. Centeno C, Rojí R, Portela MA, et al Improved cancer-related fatigue in a randomise

2. (Placebo, score 4) valence of proposed|
Row 4: |diagnostic criteria in a United States sample of cancer survivors.J Clin Oncol. 2001;19(14):3385.|
Row 5: |3. Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T, Palmer JL . Patient-controlled methylphenidate for|
Row 6: |cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2006;24(13):2073.|
Row 7: |4. Spathis A, Dhillan R, Booden D, Forbes K, Vrotsou K, Fife K. Modafinil for the treatment of fatigue in lung|
Row 8: |cancer: a pilot study. Palliat Med. 2009;23(4):325.|
Row 9: |5. Centeno C, Rojí R, Portela MA, et al Improved cancer-rel

3. (Control, score 3) ύμητες
o
Metoclopramide, αντενδείκνυται σε πλήρη απόφραξη του εντέρου. Διακοπή σε περίπτωση εμφάνισης
o
Cyclizine
o
Haloperidol
o
Levomeprom
- Hyoscine butylbr
Morphine sulpha
mazine
romide
ate
ρτικών (sen
πράνων (sod
nna, bisaco
diumdocusa
odyl
ate)
1. NECN Palliative and End of Life Care Symptoms Control Guidelines 2021(Fifth edition). Northern Cancer
alliance ,UK
2. Guidelines for symptom control. Department of palliative care. The Royal Marsden
Supportive Care in Cancer 25
3. Molassiotis, A., Aapro, M., Herrstedt, J., Gralla, R., &Roila, F. (2017). MASCC/ESMO Antiemetic Guidelines:
Introduction t

4. (Control, score 3) άνισης
o
Cyclizine
o
Haloperidol
o
Levomeprom
- Hyoscine butylbr
Morphine sulpha
mazine
romide
ate
ρτικών (sen
πράνων (sod
nna, bisaco
diumdocusa
odyl
ate)
1. NECN Palliative and End of Life Care Symptoms Control Guidelines 2021(Fifth edition). Northern Cancer
alliance ,UK
2. Guidelines for symptom control. Department of palliative care. The Royal Marsden
Supportive Care in Cancer 25
3. Molassiotis, A., Aapro, M., Herrstedt, J., Gralla, R., &Roila, F. (2017). MASCC/ESMO Antiemetic Guidelines:
Introduction to the 2016 guideline update. , (1), 267-269.
θερμίδων πρέπει να γίνεται με βαθμιαία αύξηση ξεκι

5. (Placebo, score 3) aintenance” με
pemetrexed προσέφερε όφελος επιβίωσης όταν χορηγήθηκε ως μονοθεραπεία σε ασθενείς που δεν
παρουσίασαν εξέλιξη της νόσου μετά από τέσσερις κύκλους θεραπείας με cisplatin. Η διάμεση επιβίωση ήταν
13.9 μήνες (95% CI: 12.8–16.0) για το pemetrexed και 11.0 μήνες (95% CI: 10.0–12.5) για το placebo, ενώ τα
ποσοστά επιβίωσης 1- και 2- ετών ήταν σημαντικά μεγαλύτερα για το pemetrexed (58% και 32%) έναντι του
placebo (45% και 21%). Στη μελέτη φάσης ΙΙΙ AVAPERL, εξετάστηκε το όφελος της προσθήκης pemetrexed στη
θεραπεία συντήρησης με bevacizumab μετά από 4 κύκλους αρχικής χημειοθεραπείας με
cispl

6. (Placebo, score 3) ξέλιξη της νόσου μετά από τέσσερις κύκλους θεραπείας με cisplatin. Η διάμεση επιβίωση ήταν
13.9 μήνες (95% CI: 12.8–16.0) για το pemetrexed και 11.0 μήνες (95% CI: 10.0–12.5) για το placebo, ενώ τα
ποσοστά επιβίωσης 1- και 2- ετών ήταν σημαντικά μεγαλύτερα για το pemetrexed (58% και 32%) έναντι του
placebo (45% και 21%). Στη μελέτη φάσης ΙΙΙ AVAPERL, εξετάστηκε το όφελος της προσθήκης pemetrexed στη
θεραπεία συντήρησης με bevacizumab μετά από 4 κύκλους αρχικής χημειοθεραπείας με
cisplatin/pemetrexed/bevacizumab. Στη μελέτη αυτή, αναδείχθηκε όφελος στην επιβίωση ελεύθερη υποτροπής
(πρ•ω τεύον καταληκτ

7. (Placebo, score 3) resectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar
34.Bruix J, Qin S, Merle P, Granito A et al ; RESORCE Investigators. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-
blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66. Epub 2016 Dec 6
35.Abou-Alfa GK, Meyer T, Cheng AL et al ; Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med. 2018 Jul 5;379(1):54-63
36.Zhu AX, Kang YK, Yen CJ ae al , ; REACH-2 study invest

8. (Placebo, score 3) gressing
hepatocellular carcinoma. N Engl J Med. 2018 Jul 5;379(1):54-63
36.Zhu AX, Kang YK, Yen CJ ae al , ; REACH-2 study investigators. Ramucirumab after sorafenib in patients
with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282-296.
37.El-Khoueiry AB, Sangro B, Yau T et al; Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet.
2017 Jun 24;389(10088):2492

9. (Placebo, score 2) 010 Jan-
Feb;16(1):53-61.
74.Sirohi B, Arnedos M, Popat S,Platinum-based chemotherapy in triple-negative breast cancer.Ann Oncol.
2008 Nov;19(11):1847-52. Epub 2008 Jun 20
75.Angelo Di Leo, Henry L. Gomez, Zeba Aziz. Phase III, Double-Blind, Randomized Study Comparing
Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast
Cancer J Clin Oncol 26:5544-5552,2008
76.Kimberly L. Blackwell, Harold J. Burstein, Anna Maria Storniolo Randomized Study of Lapatinib Alone or
in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastat

10. (Placebo, score 2) κριση σε σύγκριση με τη μονοθεραπεία με
γεμσιταμπίνη ή βινορελμπίνη (22% vs 6%) χωρίς όμως στατιστικά σημαντική διαφορά στο διάστημα
ελεύθερο προόδου νόσου (PFS 2.5 vs 3.4 μηνών), καθώς και ολική επιβίωση (OS 10.7 vs 11.7 μηνών )
τυχαιοποιήθηκαν είτε σε μονοθεραπεία με nivolumab είτε στο σκέλος του placebo. Τα αποτελέσματα
έδειξαν όφελος στο σκέλος του nivolumab τόσο στο PFS (3 vs 1.8 μηνών), όσο και στο OS (10.2 vs 6.9
• των ασθενών, μέσο PFS 6 μηνών και ολική επιβίωση 11.2 μηνών.
Σε ασθενείς που για οποιοδήποτε λόγο δεν έχει δοθεί pemetrexed, η χορήγηση του ως δεύτερη γραμμή
τυχαιοποιήθηκαν είτε να

## Outcome

1. (Efficacy, score 3) Sep 28
solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi:
10.1016/S1470-2045(19)30691-6,PMID: 31838007; PMCID: PMC7461630.
110. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried
M, Diaz LA Jr et al, Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite
Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin
Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. PMID: 31682550; PMCID: PMC8184060.
111. Subbiah V, Wolf J, Konda B, Kang H,

2. (Efficacy, score 3) νοθεραπεία.
Σημείωση: O συνδυασμός Doxorubicin και Trabectedin στη θεραπεία πρώτης γραμμής βρέθηκε ότι αυξάνει σημαντικά i. Fulvestrant
ii. Megestrolacetate
iii. Medroxyprogesteroneacetate
iv. GnRHanalogs
Meri
expre
Onco
ic-Bernstam F, Ma
essing solid tumo
ology Annual Mee
akker V, Oaknin A, et al. Efficacy and safety of trastuzu
ors: DESTINYPanTumor02 interim results. Presente
eting; June 2–6, 2023; Chicago, Illinois.
umab deruxtecan in patients with HER2-
ed at the American Society of Clinical του ανθρώπινου θηλώματος (HPV). Ο εμβολιασμός, έναντι υποτύπων του ιού HPV, δεν αναιρεί τις ισχύουσες
Το θε

3. (Safety, score 3) ημείωση: O συνδυασμός Doxorubicin και Trabectedin στη θεραπεία πρώτης γραμμής βρέθηκε ότι αυξάνει σημαντικά i. Fulvestrant
ii. Megestrolacetate
iii. Medroxyprogesteroneacetate
iv. GnRHanalogs
Meri
expre
Onco
ic-Bernstam F, Ma
essing solid tumo
ology Annual Mee
akker V, Oaknin A, et al. Efficacy and safety of trastuzu
ors: DESTINYPanTumor02 interim results. Presente
eting; June 2–6, 2023; Chicago, Illinois.
umab deruxtecan in patients with HER2-
ed at the American Society of Clinical του ανθρώπινου θηλώματος (HPV). Ο εμβολιασμός, έναντι υποτύπων του ιού HPV, δεν αναιρεί τις ισχύουσες
Το θεραπευτικό π

4. (Outcome, score 2) irgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and
lymphoma: findings of the European Cander Anaemia Survey. Eur J Haematol 2006;77:378-386.
8.  (last accessed 8 May 2009).
9. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and long-term outcome.
Oncology 2005;69 Suppl 2:2-7.
αρχική εκτίμηση και η περιοδική παρακολούθηση της οστικής μάζας με Dexa scan στην ΟΜΣΣ, το ισχίο (αυχένα
διατροφικών συμπληρωμάτων), είναι τουλάχιστον 1000 mg για άνδρες ηλικίας 19 έως 70 ετών και 1200 mg
ανά ημέρα για άνδρες ηλικίας 71 ετών και άνω και για τις μετεμμ

5. (Efficacy, score 2) he Phase II KEYNOTE-158 Study. J Clin
Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. PMID: 31682550; PMCID: PMC8184060.
111. Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K,
Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of
selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours
(LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: a)
Στάδια IA και ΙΒ σε όγκους χαμηλής διαφοροποίησης (grade 3)
b)
Στάδια ΙC-IV
ΘΕΡΑΠ

6. (Efficacy, score 2) –101.
4. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and
vomiting (CINV): a comprehensive review. Ann Oncol. 2015 Jun;26(6):1081-90.
5. Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D. Aprepitant and fosaprepitant: a 10-year
review of efficacy and safety. Oncologist. 20 Apr;20(4):450-458.
6. Antiemesis, NCCN guidelines, version 4.2020 at:
7. SANCUSO περίληψη χαρακτηριστικών προϊόντος
8. Larkin et al, Diagnosis, assessment and management of constipation in advanced cancer ESMO clinical
practice guidelines Annals of Oncology 29 (Supplement

7. (Efficacy, score 2) our years of experience,
. 2010 Jun; 56(6): 514–517
4. Khanna I, Pillarisetti S, Buprenorphine – an attractive opioid with underutilized potential in treatment of
chronic pain, Journal of pain research, volume 2015: 8 pages 859-870.
5. Raffa R, Ding Z.,Examination of the preclinical antinociceptive efficacy of buprenorphine and its
designation as full- or partial-agonist, Acute Pain2007;145-152.
6. Pergolizzi J, Aloisi AM, Filitz J, Langford R, Likar R, Mercadante S et al, Current Knowledge of
Buprenorphine and Its Unique Pharmacological Profile, Pain Practice 2010; 10; 428-450.
7. Virk Ms, Arttamangl

8. (Efficacy, score 2) insworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus
Row 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a Row 1: review of 56 cases. Cancer 1987; 59:572.
Row 2: 44. Mukai H, Katsumata N, Ando M, et al. Safety and efficacy of a combination of docetaxel and cisplatin in
Row 3: patients with unknown primary cancer. Am J Clin Oncol. 2010;33:32–35.
Row 4: 45. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-
Row 5: fluorouracil with or without docetaxel for larynx pr

9. (Efficacy, score 2) n
Row 7: Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical
Row 8: Trial. JAMA 2017; 318:1047.
Row 9: 7. Boettger S, Jenewein J, Breitbart W. Haloperidol, risperidone, olanzapine and aripiprazole in the
Row 10: management of delirium: A comparison of efficacy, safety, and side effects. Palliat Support Care. 2015 Row 1: Νόσημα|Εμπορική ονομασία εμβολίου|Σύσταση|Χρονισμός|Παρατηρήσεις
Row 2: Γρι�πη|Fluarix, Influvac, Vaxigrip Fulcelvax, Fluad, Efluelda|Ετη�σιος εμβολιασμο�ς για ο�λους. Δυνητικα� με “ενισχυμε�νο” εμβο�λιο για τους 65 ετω�ν και α�νω|Αρχε�ς

10. (Safety, score 2) EYNOTE-158 Study. J Clin
Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. PMID: 31682550; PMCID: PMC8184060.
111. Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K,
Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of
selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours
(LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: a)
Στάδια IA και ΙΒ σε όγκους χαμηλής διαφοροποίησης (grade 3)
b)
Στάδια ΙC-IV
ΘΕΡΑΠΕΙΑ ΣΥΝΤΗΡΗ

